Icon (NASDAQ:ICLR) Price Target Raised to $130.00 at JPMorgan Chase & Co.

Icon (NASDAQ:ICLR) had its price target upped by JPMorgan Chase & Co. from $120.00 to $130.00 in a research note released on Friday,Benzinga reports. JPMorgan Chase & Co. currently has a neutral rating on the medical research company’s stock.

Several other equities research analysts have also issued reports on ICLR. Royal Bank Of Canada increased their price objective on shares of Icon from $123.00 to $126.00 and gave the stock a “sector perform” rating in a research report on Friday. Zacks Research lowered shares of Icon from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 25th. Robert W. Baird set a $119.00 price objective on shares of Icon in a research report on Friday, February 13th. Bank of America reissued an “underperform” rating and issued a $105.00 price objective on shares of Icon in a research report on Wednesday. Finally, Piper Sandler lowered shares of Icon to a “neutral” rating in a research report on Thursday. Seven investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, Icon presently has an average rating of “Hold” and a consensus price target of $153.00.

Icon Stock Performance

NASDAQ:ICLR opened at $136.07 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31. The company has a market cap of $10.99 billion, a P/E ratio of 22.09, a P/E/G ratio of 3.57 and a beta of 1.23. Icon has a fifty-two week low of $66.57 and a fifty-two week high of $211.00. The firm’s 50 day moving average is $113.06 and its two-hundred day moving average is $141.46.

Icon (NASDAQ:ICLR) last released its quarterly earnings data on Wednesday, June 3rd. The medical research company reported $2.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.13 by ($0.61). Icon had a return on equity of 10.58% and a net margin of 7.40%.The business had revenue of $2.11 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same period in the previous year, the company earned $3.43 EPS. Icon’s revenue was up 2.5% on a year-over-year basis. Analysts expect that Icon will post 11.53 EPS for the current year.

Institutional Trading of Icon

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. increased its position in Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock valued at $79,000 after buying an additional 56 shares in the last quarter. Sanctuary Advisors LLC increased its position in Icon by 1.1% during the 4th quarter. Sanctuary Advisors LLC now owns 4,932 shares of the medical research company’s stock valued at $899,000 after buying an additional 56 shares in the last quarter. Signaturefd LLC increased its position in Icon by 12.6% during the 4th quarter. Signaturefd LLC now owns 643 shares of the medical research company’s stock valued at $117,000 after buying an additional 72 shares in the last quarter. New Wave Wealth Advisors LLC increased its position in Icon by 5.1% during the 4th quarter. New Wave Wealth Advisors LLC now owns 1,479 shares of the medical research company’s stock valued at $270,000 after buying an additional 72 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in Icon by 0.4% during the 4th quarter. Janney Montgomery Scott LLC now owns 23,942 shares of the medical research company’s stock valued at $4,363,000 after purchasing an additional 93 shares during the last quarter. 95.61% of the stock is currently owned by institutional investors.

Icon News Roundup

Here are the key news stories impacting Icon this week:

• Positive Sentiment: BMO Capital Markets raised its target on Icon Plc to $160 from $130 and kept an outperform rating, suggesting meaningful upside potential. Benzinga
• Positive Sentiment: Barclays lifted its price target to $150 from $120, with an equal weight rating, signaling improved expectations for the stock. Tickerreport.com
• Positive Sentiment: Citigroup increased its target to $140 from $120, implying modest upside from current levels, though it kept a neutral stance. Tickerreport.com
• Neutral Sentiment: JPMorgan raised its target to $130 from $120 but kept a neutral rating, reflecting a more cautious view than some peers. Benzinga
• Neutral Sentiment: Icon reported fourth-quarter earnings that missed estimates, but revenue came in above expectations and the company highlighted strong bookings despite ongoing revenue challenges. Yahoo Finance
• Negative Sentiment: Icon disclosed a material weakness in internal controls, which raises concerns about financial reporting quality and potential regulatory risk. TipRanks
• Negative Sentiment: The company also cut FY 2026 EPS guidance to $10.00-$11.00, below Wall Street expectations, which likely pressured the stock after earnings. Financial News

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.